Posts by Sandra Ansanay-Alex
Moderna plans to produce a RNA vaccine against RSV in Valais
Moderna, which developed one of the first messenger RNA vaccines against Covid-19, has disclosed positive preliminary results for a trial against the Respiratory Syncytial Virus (RSV), which causes bronchiolitis, in the elderly. The vaccine will be produced in Boston (USA) and in Visp (Switzerland) The phase 3 trial is being conducted in a double-blind…
Read MoreThe HUG open a Centre for Virtual Medicine
The new Centre for Virtual Medicine at the HUG is a pioneer in the use of virtual reality for clinical research and medical practice. The Centre for Virtual Medicine (CMV) is the result of collaboration between the Departments of Diagnostics, Clinical Neurosciences and Medicine and the Swiss Federal Institute of Technology in Lausanne (EPFL).…
Read MoreBIONOMOUS closes a USD 2.7 million Series A
The Swiss-based startup builds devices to automate processes in Life Science research and prepares a product rollout and expansion. The round was led by Nivalis Group, a Swiss Holding based in Villaz-St-Pierre, with participation from Cybernetix Ventures, a leading robotics-focused US venture capital firm based in the Boston, and Capital Risque Fribourg, an early-stage…
Read MoreVirtual reality glasses used as a diagnostic tool for brain disorders
MachineMD, a spin-off of Inselspital Bern, and CSEM, are collaborating to diagnose brain diseases by analyzing eye movements with a virtual reality headset. Their tool, neos, has been awarded the first prize by the Ypsomed Innovation Fund. machineMD is an exemplary product of the well-connected Bernese startup ecosystem. Prof Dr Mathias Abegg has been…
Read MoreNeurosoft Bioelectronics receives ISO Certification for its Quality Management System
Neurosoft Bioelectronics SA, a startup developing implantable brain-computer interfaces, announces that it has received ISO 13485:2016 Certification by TÜV SÜD for its Quality Management System. This is a major milestone for Neurosoft Bioelectronics as it brings the company one step closer to its first clinical studies and regulatory approval of their first product :…
Read MoreA CHF 1 billion contract for Bachem Group
The contract covers the delivery of a large volume of peptides over a five-year period from 2025-2029, and follows the conclusion of two large volume contracts announced in September 2022. The customer’s name is undisclosed. Bachem is pursuing an investment programme across all sites to expand capacity, especially in Vionnaz (Switzerland). A modern large-scale facility…
Read MoreYpsomed Innovation Award 2022 – The Winners
machineMD (1st place), Pace Locator (2nd place) and Compact Motion (3rd place). The Innovation Award, worth a total of CHF 100,000, is presented every two years by the Ypsomed Innovation Fund Foundation. The aim is to promote the transfer of knowledge and technology from universities of applied sciences and universities in the “Espace Mittelland” region.…
Read MoreA CHF 1.5M seed-funding round for MPC Therapeutics to improve CAR-T cancer therapies
MPC Therapeutics (MPC Tx), is a Swiss biotechnology company based in Geneva, focusing on metabolism and cellular rejuvenation. The company announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx’s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by…
Read MoreSwissfillon becomes ten23 health
ten23 health®, a global contract development and manufacturing organization (CDMO) announces the change in branding of its in Visp, Switzerland based filling operation from swissfillon to ten23 health. This represents a natural progression since the acquisition of swissfillon by ten23 health in October 2021 and is intended to unify the company’s operations under a…
Read MoreSTALICLA signs exclusive in-licensing agreement with Novartis for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications. STALICLA SA, a clinical-stage, Geneva-based, biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, announces that it has entered into an exclusive…
Read More